We observed positive SATB2 immunostaining in 80.8% of CRC cases, which is consistent with results presented in the recent meta-analysis by Maguire et al., who reported SATB2 expression in 81% of CRCs [41]. Here, SATB2 is linked to colorectal carcinoma.